Literature DB >> 20557310

Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients.

Kentaro Tamaki1, Hironobu Sasano, Takanori Ishida, Minoru Miyashita, Motohiro Takeda, Masakazu Amari, Nobumitsu Tamaki, Noriaki Ohuchi.   

Abstract

The roles of core needle biopsy (CNB) have become well established as an important preoperative diagnostic method for breast lesions. We examined the concordance of histological types, nuclear grades, hormone receptors, and human epidermal growth factor receptor 2 (HER2) status between CNB and surgical specimens in 353 cases. In addition, we analyzed the correlation between the number of CNB specimens obtained and accuracy of histological factors in order to explore the optimal number of CNB specimens. Between CNB and surgical specimens, concordance rates of histological type, nuclear grade, estrogen receptor (ER), and progesterone receptor (PgR) status (cut-off 0-<1%, 1-10%, and 10%<), and HER2 were 84.4%, 81.3%, 92.9%, and 89.3%, respectively. In 52 of 353 patients who were histopathologically diagnosed as ductal carcinoma in situ (DCIS) by CNB, final diagnosis was changed in to invasive ductal carcinoma (IDC) in surgical specimens. Statistically significant differences were detected in the discrepancy of the following factors between CNB and subsequent surgical specimens: histological types, nuclear grade, and PgR, between patients who received four or more cores and those who had received three or less cores. In addition, a similar tendency was also detected in estrogen receptor (ER) and HER2 as in the above, and the cases that received four cores reached to 100% concordance in diagnosis between CNB and surgical specimens. Therefore, the optimal numbers of CNB were considered four at least in assessing the histological type, invasion, nuclear grade, hormone receptor status, and HER2 status of individual patients in the preoperative setting.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20557310     DOI: 10.1111/j.1349-7006.2010.01630.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  25 in total

1.  Are biopsy specimens predictive of HER2 status in gastric cancer patients?

Authors:  M Pirrelli; M L Caruso; M Di Maggio; R Armentano; A M Valentini
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

2.  Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases.

Authors:  Jie Chen; Zu Wang; Qing Lv; Zhenggui Du; Qiuwen Tan; Di Zhang; Bingjun Xiong; Helin Zeng; Juxiang Gou
Journal:  Pathol Oncol Res       Date:  2017-01-10       Impact factor: 3.201

3.  Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers.

Authors:  Yu-Jie Shi; Julia Y S Tsang; Yun-Bi Ni; Gary M Tse
Journal:  Oncologist       Date:  2017-03-24

4.  Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.

Authors:  M Pölcher; M Braun; M Tischitz; M Hamann; N Szeterlak; A Kriegmair; C Brambs; C Becker; O Stoetzer
Journal:  Arch Gynecol Obstet       Date:  2021-02-14       Impact factor: 2.344

5.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.

Authors:  Ji Hyun Youk; Eun Ju Son; Jin Chung; Jeong-Ah Kim; Eun-Kyung Kim
Journal:  Eur Radiol       Date:  2012-04-17       Impact factor: 5.315

Review 6.  Status quo and development trend of breast biopsy technology.

Authors:  Yan-Jun Zhang; Lichun Wei; Jie Li; Yi-Qiong Zheng; Xi-Ru Li
Journal:  Gland Surg       Date:  2013-02

7.  Testing for her2 in breast cancer: current pathology challenges faced in Canada.

Authors:  W Hanna; P Barnes; R Berendt; M Chang; A Magliocco; A M Mulligan; H Rees; N Miller; L Elavathil; B Gilks; N Pettigrew; D Pilavdzic; S Sengupta
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

8.  Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.

Authors:  Giuseppe Bogina; Laura Bortesi; Marcella Marconi; Marco Venturini; Gianluigi Lunardi; Francesca Coati; Alberto Massocco; Erminia Manfrin; Cristina Pegoraro; Giuseppe Zamboni
Journal:  Virchows Arch       Date:  2011-06-04       Impact factor: 4.064

9.  Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients.

Authors:  Wen-Kai Ge; Ben Yang; Wen-Shu Zuo; Gang Zheng; Ying-Qi Dai; Chao Han; Li Yang; Mei-Zhu Zheng
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

10.  ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.

Authors:  Alec Vaezi; Chelsea H Feldman; Laura J Niedernhofer
Journal:  Pharmgenomics Pers Med       Date:  2011-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.